Stockscreener 앱 받기
11.98
1.70%
0.20
시간 외 거래:
11.73
-0.25
-2.09%
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
FDA delays Kalvista’s sebetralstat decision due to resource constraints By Investing.com - Investing.com Nigeria
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’ - BioPharma Dive
FDA delays Kalvista’s sebetralstat decision due to resource constraints - Investing.com
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis - BioSpace
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Pat - GuruFocus
KalVista’s oral HAE treatment shows efficacy for breakthrough attacks By Investing.com - Investing.com Canada
DRI Healthcare Notes FDA Delay for KalVista's' Sebetralstat New Drug Approval on "Resourcing" Issues - MarketScreener
Kalvista stock steady as JMP reiterates $19 target amid FDA delay - Investing.com Canada
Kalvista stock steady as JMP reiterates $19 target amid FDA delay By Investing.com - Investing.com South Africa
DRI Healthcare Trust Reports FDA Delay on KalVista’s Sebetralstat Decision - MSN
FDA won’t meet PDUFA goal date for sebetralstat - The Pharma Letter
DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals' Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints - Weekly Voice
US FDA extends review of KalVista's swelling disorder drug due to heavy workload - Reuters
FDA Tells Drugmaker ‘Heavy Workload’ to Delay Approval Decision - Bloomberg
FDA cites ‘resource constraints' in delay of local biotech's drug approval decision - The Business Journals
KalVista (KALV) Shares Decline as FDA Delays Drug Review - GuruFocus
FDA delays decision on KalVista’s HAE treatment sebetralstat By Investing.com - Investing.com India
KalVista said FDA will not meet review date for sebetralstat (KALV) - Seeking Alpha
KalVista (KALV) Awaits FDA Decision on Sebetralstat Due to Revie - GuruFocus
Kalvista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date For Sebetralstat NDA - marketscreener.com
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints - Business Wire
Two Sigma Investments LP Has $114,000 Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KALV’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
Research Analysts Issue Forecasts for KALV FY2026 Earnings - Defense World
Two Sigma Advisers LP Sells 15,500 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Bank of America Corp DE Has $932,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Buy” from Analysts - Defense World
Transcript : KalVista Pharmaceuticals, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - MarketScreener
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 - BioSpace
KalVista Pharmaceuticals to Present New Sebetralstat Data at the - GuruFocus
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 | KALV Stock News - GuruFocus
Ameriprise Financial Inc. Takes $452,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
ProShare Advisors LLC Purchases New Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 - BioSpace
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus
BNP Paribas Financial Markets Has $53,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
(KALV) Technical Pivots with Risk Controls - news.stocktradersdaily.com
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management - marketscreener.com
KalVista (KALV) Shows Promising Sebetralstat Results for Heredit - GuruFocus
KalVista (KALV) Shows Promising Sebetralstat Results for Hereditary Angioedema | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Medical Congress Presentations Highligh - GuruFocus
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management | KALV Stock News - GuruFocus
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Reduces Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Deutsche Bank AG Grows Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals to Present at the Jefferies Global Heal - GuruFocus
KalVista Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - BioSpace
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
0.68%
0.50%
자본화:
|
볼륨(24시간):